Page 110 - 南京医科大学自然版
P. 110
第45卷第5期
·696 · 南 京 医 科 大 学 学 报 2025年5月
品。材料学家和眼科医生在促进水凝胶临床转化 [6] 吴 迪,王 萍,雷 晨,等. 负载抗菌多肽温敏水凝胶
过程中需解决技术和人体安全性评估等问题,未来 的制备及性能研究[J]. 南京医科大学学报(自然科学
应着重研究药物释放机制和速率,结合不同疾病的 版),2022,42(7):957-964
发病机制进一步优化水凝胶系统的设计,以推动其 WU D,WANG P,LEI C,et al. Preparation and properties
of antimicrobial peptide⁃loaded thermosensitive hydro⁃
临床应用。
gel[J]. Journal of Nanjing Medical University(Natural
本综述探讨了水凝胶在视网膜疾病治疗中的
Sciences),2022,42(7):957-964
研究进展,尽管大多数研究仍处于临床前阶段,但 [7] ARAGÓN⁃NAVAS A,LÓPEZ⁃CANO J J,JOHNSON M,
预计部分将顺利进入临床试验,并最终应用于临床 et al. Smart biodegradable hydrogels:drug⁃delivery plat⁃
实践。文章旨在为未来的研究和临床应用提供参 forms for treatment of chronic ophthalmic diseases affect⁃
考,以期改善治疗效果并提高患者的生活质量。 ing the back of the eye[J]. Int J Pharm,2024,649:
利益冲突声明: 123653
本文作者声明不存在任何与本稿件相关的利益冲突。 [8] ALONSO J M,ANDRADE DEL OLMO J,PEREZ GON⁃
Conflict of Interests: ZALEZ R,et al. Injectable hydrogels:from laboratory to
The authors of this article declare that there is no conflict industrialization[J]. Polymers,2021,13(4):650
[9] 赵 婵,刘 昊,陈洁莹,等. 温度/超声双重响应型相
of interests related to this manuscript.
作者贡献声明: 变液滴对水凝胶结构性能的调控[J]. 南京医科大学学
所有作者都为研究概念和设计作出了贡献。材料准备、 报(自然科学版),2022,42(7):948-956
数据分析由徐静逸完成。初稿由徐静逸撰写,胡仔仲对稿件 ZHAO C,LIU H,CHEN J Y,et al. Structure and proper⁃
的内容进行了评价。 ties regulation of hydrogels by temperature/ultrasound du⁃
Author’s Contributions: al⁃responsive phase⁃change droplets[J]. Journal of Nan⁃
jing Medical University(Natural Sciences),2022,42(7):
All authors contributed to the study conception and design.
948-956
The material preparation and data analysis were performed by
[10]RAFAEL D,GUERRERO M,MARICAN A,et al. Deliv⁃
XU Jingyi. The first draft of the manuscript was written by XU
ery systems in ocular retinopathies:the promising future
Jingyi,and HU Zizhong commented on previous versions of the
of intravitreal hydrogels as sustained⁃release scaffolds[J].
manuscript.
Pharmaceutics,2023,15(5):1484
[参考文献]
[11]TORKASHVAND A,IZADIAN A,HAJRASOULIHA A.
[1] LANZETTA P,KOROBELNIK J F,HEIER J S,et al. In⁃ Advances in ophthalmic therapeutic delivery:a compre⁃
travitreal aflibercept 8 mg in neovascular age⁃related mac⁃ hensive overview of present and future directions[J].
ular degeneration(PULSAR):48⁃week results from a ran⁃ Surv Ophthalmol,2024,69(6):967-983
domised ,double ⁃ masked ,non ⁃ inferiority ,phase 3 [12]HAMMER M,HERTH J,MUUSS M,et al. Forward light
trial[J]. Lancet,2024,403(10432):1141-1152 scattering of first to third generation vitreous body replace⁃
[2] LIN K T,WANG A,NGUYEN A B,et al. Recent advanc⁃ ment hydrogels after surgical application compared to con⁃
es in hydrogels:ophthalmic applications in cell delivery, ventional silicone oils and vitreous body[J]. Gels,2023,9
vitreous substitutes,and ocular adhesives[J]. Biomedi⁃ (10):837
cines,2021,9(9):1203 [13]HENNINK W E,VAN NOSTRUM C F. Novel crosslink⁃
[3] LIU Z,LIOW S S,LAI S L,et al. Retinal⁃detachment re⁃ ing methods to design hydrogels[J]. Advanced Drug De⁃
pair and vitreous⁃like⁃body reformation via a thermogel⁃ livery Reviews,2002,54(1):13-36
ling polymer endotamponade[J]. Nat Biomed Eng,2019, [14]JOGLEKAR M,TREWYN B G. Polymer⁃based stimuli⁃re⁃
3(8):598-610 sponsive nanosystems for biomedical applications[J]. Bio⁃
[4] MONDELO⁃GARCÍA C,BANDÍN⁃VILAR E,GARCÍA⁃ technol J,2013,8(8):931-945
QUINTANILLA L,et al. Current situation and challenges [15]RADHAKRISHNAN J,KRISHNAN U M,SETHURA⁃
in vitreous substitutes[J]. Macromol Biosci,2021,21 MAN S. Hydrogel based injectable scaffolds for cardiac
(8):e2100066 tissue regeneration[J]. Biotechnol Adv,2014,32(2):
[5] HAM Y,MEHTA H,KANG⁃MIELER J,et al. Novel drug 449-461
delivery methods and approaches for the treatment of reti⁃ [16]XUE K,ZHAO X,ZHANG Z,et al. Sustained delivery of
nal diseases[J]. Asia Pac J Ophthalmol,2023,12(4): anti⁃VEGFs from thermogel depots inhibits angiogenesis
402-413 without the need for multiple injections[J]. Biomater Sci,

